Roche unveiled a comprehensive strategy to become a top three player in the obesity market by 2030. CEO Teresa Graham emphasized the company’s robust pipeline, commercial capabilities, and integrated pharma-diagnostics approach as key differentiators. Roche plans to advance Carmot Therapeutics’ dual GLP-1/GIP receptor injectable CT-388 into phase 3 trials next year, alongside an oral GLP-1 candidate CT-996 in phase 2. The strategy complements Roche’s $1.6 billion deal to co-develop Zealand Pharma's amylin analog petrelintide. Roche projects peak sales exceeding $3 billion for CT-388 and petrelintide combined, underscoring its seriousness about competing in the weight-loss arena.